This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Mood disorders
  • /
  • Depression in adults: recognition and management
Guideline

Depression in adults: recognition and management

Read time: 1 mins
Last updated:28th Oct 2009
Status: Live
Depression in adults: recognition and management


This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment.

- MHRA advice on antiepileptic drugs in pregnancy: In January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) updated safety advice on antiepileptic drugs in pregnancy. We are reviewing the recommendations on carbamazepine and lamotrigine in this guideline, and will amend them as needed. In the meantime, take account of MHRA advice when discussing treatment with women and girls of childbearing potential.

- MHRA advice on valproate: We have amended a recommendation in the section on combining and augmenting medications in line with the MHRA guidance on valproate use by women and girls. Valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless other options are unsuitable and the pregnancy prevention programme is in place. The MHRA has published temporary advice on the valproate pregnancy prevention programme during the COVID-19 pandemic.

NICE has also produced a guideline on depression in adults with a chronic physical health problem.


Read full Guideline